Survival impact of involvement of lymph node stations 16b1, 9, and 8a during pancreatoduodenectomy for pancreatic and periampullary cancers (PANODE): prospective multicentre study.

@article{suurmeijer2026survival,
  title = {{Survival impact of involvement of lymph node stations 16b1, 9, and 8a during pancreatoduodenectomy for pancreatic and periampullary cancers (PANODE): prospective multicentre study.}},
  author = {J Annelie Suurmeijer and Bobby K Pranger and Leonard W F Seelen and Mahsoem Ali and L Bengt van Rijssen and Dorine S Tseng and Tara M Mackay and Jacob L van Dam and Hjalmar C van Santvoort and Bas Groot Koerkamp and Arantza Farina Sarasqueta and Casper H van Eijck and Mike S L Liem and Geert Kazemier and Vincent B Nieuwenhuijs and Ignace H de Hingh and Joost M Klaase and Joris I Erdmann and Olivier R Busch and I Quintus Molenaar and Vincent E de Meijer and Marc G Besselink and Dutch Pancreatic Cancer Group},
  journal = {BJS open},
  year = {2026},
  month = sep,
  doi = {10.1093/bjsopen/zrag157},
  url = {https://europepmc.org/article/MED/42905970},
  note = {CC BY-NC},
}

TY  - JOUR
TI  - Survival impact of involvement of lymph node stations 16b1, 9, and 8a during pancreatoduodenectomy for pancreatic and periampullary cancers (PANODE): prospective multicentre study.
AU  - J Annelie Suurmeijer
AU  - Bobby K Pranger
AU  - Leonard W F Seelen
AU  - Mahsoem Ali
AU  - L Bengt van Rijssen
AU  - Dorine S Tseng
AU  - Tara M Mackay
AU  - Jacob L van Dam
AU  - Hjalmar C van Santvoort
AU  - Bas Groot Koerkamp
AU  - Arantza Farina Sarasqueta
AU  - Casper H van Eijck
AU  - Mike S L Liem
AU  - Geert Kazemier
AU  - Vincent B Nieuwenhuijs
AU  - Ignace H de Hingh
AU  - Joost M Klaase
AU  - Joris I Erdmann
AU  - Olivier R Busch
AU  - I Quintus Molenaar
AU  - Vincent E de Meijer
AU  - Marc G Besselink
AU  - Dutch Pancreatic Cancer Group
PY  - 2026
DA  - 2026/09/01
JO  - BJS open
DO  - 10.1093/bjsopen/zrag157
UR  - https://europepmc.org/article/MED/42905970
AB  - Background  Current guidelines do not recommend routine sampling of lymph node stations (LNS) 16b1, 9, and 8a during pancreatoduodenectomy for pancreatic ductal adenocarcinoma (PDAC) and other periampullary cancers because prospective multicentre studies are lacking. This study evaluated the association between the involvement of these LNS and overall survival (OS).Methods  This prospective multicentre study included patients undergoing pancreatoduodenectomy for PDAC, distal cholangiocarcinoma, ampullary cancer, or duodenal cancer between October 2015 and April 2020. Associations between involvement of LNS 16b1, 9, and 8a and OS were analysed using multivariable Cox regression analyses.Results  Among 1218 included patients, 673 had PDAC, 228 had distal cholangiocarcinoma, 212 had ampullary cancer, and 105 had duodenal cancer. LNS 16b1 involvement was associated with worse OS in PDAC (10 versus 24 months; adjusted hazard ratio (aHR) 2.33; 95% confidence interval (c.i.) 1.62 to 3.35), distal cholangiocarcinoma (7 versus 28 months; aHR 6.95; 95% c.i. 2.88 to 16.77), ampullary cancer (9 versus 62 months; aHR 4.35; 95% c.i. 1.73 to 10.94), and duodenal cancer (13 months versus endpoint not reached; aHR 3.95; 95% c.i. 1.15 to 13.47). LNS 8a involvement was associated with worse OS in PDAC (13 versus 22 months; aHR 1.38; 95% c.i. 1.03 to 1.86), distal cholangiocarcinoma (16 versus 26 months; aHR 1.68; 95% c.i. 1.00 to 2.81), and ampullary cancer (16 versus 62 months; aHR 2.89; 95% c.i. 1.51 to 5.53). LNS 9 involvement was associated with worse OS only in ampullary cancer (4 versus 35 months; aHR 8.19; 95% c.i. 2.34 to 28.57).Conclusion  LNS 16b1 involvement was associated with poor OS in PDAC and periampullary cancer. Future studies should assess routine preoperative and intraoperative sampling of LNS 16b1 and the impact of neoadjuvant treatment.
SN  - 2474-9842
ER  -